Decentralized Clinical Trials: What the FDA's 2024 Final Guidance Allows and Guards Against

The FDA's September 2024 final guidance, titled "Conducting Clinical Trials With Decentralized Elements," permits sponsors to move trial activities off the traditional research site: telehealth visits with the investigator, appointments with a local healthcare provider, blood draws at a nearby lab, and data collected by sensors in a participant's home. What it guards against is any drift in safety or data quality that distance might introduce. The central principle is stated plainly in the guidance and its Federal Register notice: the regulatory requirements are the same whether or not a trial includes decentralized elements. Convenience for participants does not lower the bar for evidence.

This piece explains what the guidance actually allows, and where it draws firm lines. It is educational and not medical advice.

Why this guidance exists

The document is not a spontaneous policy shift. Congress directed it. Section 3606(a) of the Consolidated Appropriations Act, 2023, part of the Food and Drug Omnibus Reform Act (FDORA), instructed the FDA to issue guidance clarifying how decentralized clinical trials (DCTs) can support drug and device development. The agency published a draft in May 2023 under the title "Decentralized Clinical Trials for Drugs, Biological Products, and Devices," took public comment, and finalized it on September 18, 2024. One telling change is the title itself. The final version speaks of trials "with decentralized elements" rather than a separate category called a DCT. That reframing matters: the FDA is describing a spectrum of design choices layered onto ordinary trials, not a new regulatory species with its own rules.

For diabetes therapeutics, where trials often run long, enroll broadly, and depend on repeated glucose and weight measurements, decentralized elements are attractive. A participant in a rural county can join a study without a weekly drive to an academic center. But the same features that widen access also spread the trial across many hands and locations, and that is precisely what the guidance is built to manage.

What the guidance allows

The guidance endorses a menu of decentralized elements. Telehealth can substitute for in-person visits when a task does not require a physical exam or on-site procedure. Local healthcare providers and local clinical laboratories, ones not otherwise involved in the trial, can perform routine tasks such as a standard blood draw or an imaging study close to where a participant lives. Trial personnel can conduct visits at a participant's home. Digital health technologies, including wearables and connected devices, can capture data remotely between visits.

Two ideas run through all of it. First, tasks should be matched to the setting and the skill they require. A complex assessment central to a study's primary endpoint belongs with trained trial staff, while a routine, widely performed procedure can reasonably be delegated locally. Second, variability is the enemy. The guidance repeatedly stresses that protocols should include specific instructions for how each decentralized activity is performed, so that a measurement taken in one participant's kitchen is comparable to one taken in another's, or at a site.

What it guards against

The safeguards cluster around three risks: fragmented oversight, inconsistent data, and gaps in participant safety.

Oversight that does not dissolve with distance

The investigator remains responsible for the conduct of the trial even when activities happen far from the site. The guidance describes how a local healthcare provider can perform a specified, routine task without becoming a formally listed sub-investigator, provided that provider is doing standard clinical care rather than exercising trial-specific judgment. The trial is expected to keep a record of who did what, so accountability is traceable across every location. Sponsors carry a coordination duty: they must ensure the various decentralized activities fit together and that data flowing in from many inputs can be reconciled.

Data that stays trustworthy

When participants perform tasks themselves, such as a self-administered test at home, the guidance calls for clear instruction, for example through telehealth or pre-recorded video, so the task is done correctly. When digital health technologies transfer data from remote locations, sponsors must confirm those tools are secure and suitable for the purpose. The FDA points to its separate December 2023 guidance, "Digital Health Technologies for Remote Data Acquisition in Clinical Investigations," for the detail on selecting and verifying such tools. That companion document addresses the content Congress described in section 3606(b).

Safety that reaches the participant

A decentralized design cannot leave a participant without a clear path to care if something goes wrong. The guidance addresses how adverse events are identified, reported, and managed when visits happen remotely or locally, and how an investigator maintains a line of oversight for participant safety. It also treats the practical mechanics that decentralization introduces, including how investigational products are handled and, where appropriate, shipped, and informed consent obtained, potentially through remote or electronic means, without weakening the participant's understanding of the study.

How to read it well

The most common misreading is to treat the guidance as a green light to decentralize everything. It is not. It is a framework for deciding, element by element, whether moving an activity off-site preserves the safety and integrity that regulation demands. Some assessments will always belong at a site. The value of the document is that it makes those trade-offs explicit rather than leaving each sponsor to improvise.

For the diabetes field specifically, this creates a credible route to trials that enroll the populations most affected by disease, including people far from research hubs, while holding the evidence to the standard that regulators, clinicians, and patients rely on. The guidance widens the door without lowering the threshold. That balance, access without compromised rigor, is the useful thing to carry away from it.